Biologic Therapies in Myasthenia Gravis

Henry Kaminski, MD


May 24, 2022

Myasthenia gravis (MG) develops when autoantibodies against the acetylcholine receptor cause a breakdown in communication between nerves and muscles.

The resulting weakness and rapid fatigue of skeletal muscles can occur in multiple muscle groups, which is known as generalized MG and is by far the most common form of the disease.

Dr Henry Kaminski from George Washington University discusses how the management of generalized MG has evolved, leading to the introduction of biologic therapies.

He focuses on the complement inhibitor eculizumab as well as neonatal Fc receptor inhibitors, including efgartigimod, which was recently approved for use in MG by the US Food and Drug Administration.

Dr Kaminski comments that the optimal role of these therapies will evolve, but currently they offer important options for patients who have had inadequate response to other therapies.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.